Literature DB >> 16272340

Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus.

Min Fang1, Luis J Sigal.   

Abstract

It is believed that CD8+ T lymphocytes or Abs can independently clear many primary viral infections, including those caused by Orthopoxviruses (OPV), a genus that includes the human pathogens variola and monkeypox and the vaccine species vaccinia virus. However, most experiments addressing the role of Abs and CD8+ T cells in protection have used viruses that are not specific for the host. In the present study, we used the mouse-specific OPV ectromelia virus and mice deficient in CD40, B cells, or CD8+ T cells and adoptive transfers of CD8+ T or B lymphocytes to show that the protection afforded by CD8+ T cells is incomplete. Despite sustained CD8+ T cell responses, in the absence of Ab responses ectromelia virus persists. This results in delayed disease and inexorably leads to death. Therefore, CD8+ T lymphocytes and Abs are not redundant but complementary and essential to survive infections with a highly pathogenic viruses in the natural host.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272340     DOI: 10.4049/jimmunol.175.10.6829

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  66 in total

1.  Perforin-dependent CD4+ T-cell cytotoxicity contributes to control a murine poxvirus infection.

Authors:  Min Fang; Nicholas A Siciliano; Adam R Hersperger; Felicia Roscoe; Angela Hu; Xueying Ma; Ahamed R Shamsedeen; Laurence C Eisenlohr; Luis J Sigal
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

2.  Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function.

Authors:  Vijay Panchanathan; Geeta Chaudhri; Gunasegaran Karupiah
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Poxvirus-encoded gamma interferon binding protein dampens the host immune response to infection.

Authors:  Isaac G Sakala; Geeta Chaudhri; R Mark Buller; Anthony A Nuara; Hongdong Bai; Nanhai Chen; Gunasegaran Karupiah
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

4.  Comparable polyfunctionality of ectromelia virus- and vaccinia virus-specific murine T cells despite markedly different in vivo replication and pathogenicity.

Authors:  Adam R Hersperger; Nicholas A Siciliano; Laurence C Eisenlohr
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 5.  Evolutionary struggles between NK cells and viruses.

Authors:  Lewis L Lanier
Journal:  Nat Rev Immunol       Date:  2008-03-14       Impact factor: 53.106

6.  Memory CD8+ T cells specific for a single immunodominant or subdominant determinant induced by peptide-dendritic cell immunization protect from an acute lethal viral disease.

Authors:  Sanda Remakus; Daniel Rubio; Xueying Ma; Alessandro Sette; Luis J Sigal
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

7.  Characterization of ectromelia virus deficient in EVM036, the homolog of vaccinia virus F13L, and its application for rapid generation of recombinant viruses.

Authors:  Felicia Roscoe; Ren-Huan Xu; Luis J Sigal
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

8.  Memory CD8+ T cells are gatekeepers of the lymph node draining the site of viral infection.

Authors:  Ren-Huan Xu; Min Fang; Andres Klein-Szanto; Luis J Sigal
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

9.  Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry.

Authors:  Markus Cornberg; Brian S Sheridan; Frances M Saccoccio; Michael A Brehm; Liisa K Selin
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Poor Antigen Processing of Poxvirus Particles Limits CD4+ T Cell Recognition and Impacts Immunogenicity of the Inactivated Vaccine.

Authors:  Katherine S Forsyth; Brian DeHaven; Mark Mendonca; Sinu Paul; Alessandro Sette; Laurence C Eisenlohr
Journal:  J Immunol       Date:  2019-01-30       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.